Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients over 18 years old;~2. Patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases;~3. Patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs;~4. The patients voluntarily joined the study and signed the informed consent.~Exclusion Criteria:~1. Patients with contraindications to rivaroxaban anticoagulation therapy;~2. Patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy;~3. Patients with history of hemorrhagic stroke within one week;~4. Patients with cardiac benign and malignant tumors;~5. Aspirin and P2Y12 receptor antagonists should be kept;~6. In patients with severe hepatic and renal insufficiency, alanine aminotransferase \> 3 times the upper limit and total bilirubin \> 2 times the upper limit, creatinine clearance rate \< 15ml / min / 1.73m2;~7. The patient's history of intracerebral hemorrhage and active hemorrhage was 8 months;~8. Patients with hematological diseases, hemoglobin \< 100g / L, platelet \< 80 x 10\^9 / L;~9. Women with pregnancy status, planned pregnancy and lactation period;~10. Patients with life expectancy less than 1 year;~11. Patients enrolled in other clinical studies;~12. Other situations considered unsuitable by the researcher. Note: anticoagulant therapy can be given to patients with left ventricular thrombosis combined with hemorrhagic stroke ≥ 4 weeks or recent ischemic stroke / transient ischemic attack according to the specific situation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).